Coibamide A is a highly N-methylated cyclic depsipeptide derived from marine cyanobacteria. It works as a Sec61 inhibitor, blocking protein translocation into the endoplasmic reticulum and triggering apoptosis — a mechanism of action that remains rare among ADC payloads.

A recent paper reports an improved solid-phase synthesis of Coibamide A using 2-chlorotrityl resin, along with a set of 18 analogues generated to study structure-activity relationships. The best-performing analogue, [MeAla3-MeAla6]-coibamide, retained single-digit nanomolar potency (GI50 5.1-7.3 nM) across several cancer cell lines and showed lower toxicity than the natural compound in mice.

From Payload to ADC

The authors then built a full ADC: cetuximab (anti-EGFR) linked to this analogue through a cathepsin B-cleavable MC-GGFG-PAB linker. The resulting conjugate was active and target-specific both in vitro and in xenograft models, with a clear bystander killing effect. Notably, the same chemistry also worked with pertuzumab (anti-HER2), demonstrating that the platform isn’t tied to a single antibody.

The Detail That Caught Our Attention: The Linker-Payload Junction

What really stood out to us at SigutLabs is the chemistry at the linker-payload junction itself.

Normally, a PAB self-immolative unit is attached to a payload through a carbamate or an ester linkage. In this case, the payload’s own tertiary amine — its N,N-dimethyl backbone nitrogen — is directly alkylated by the PAB benzylic carbon, forming a quaternary ammonium salt right at the linker-payload junction.

This is a clever solution to a structural constraint: a tertiary amine has no N-H or O-H group available to build a conventional carbamate or ester linkage. Direct alkylation solves that problem. After cathepsin B cleaves the GGFG sequence, PAB self-immolation breaks the benzylic C-N bond and releases the payload as its native tertiary amine — traceless.

Why This Design Choice Is Smart

Beyond solving an attachment problem, this junction chemistry offers a secondary benefit: the permanent positive charge sits directly adjacent to a large, hydrophobic depsipeptide payload. Built-in charge like this is a well-established strategy against self-aggregation — a common failure mode for bulky, lipophilic payloads, particularly at high DAR.

SigutLabs’ Perspective

At SigutLabs, we design and synthesize custom ADC linkers and linker-payloads, including challenging self-immolative and charged architectures like the one described in this paper. Novel payload chemistries like Coibamide A analogues often demand equally novel linker chemistry to make them viable — exactly the kind of problem-solving we work on with our partners.

Need help with your next linker-payload design? Contact us — let’s connect.

Reference: Tian, H., Pan, W., Shi, H., Shao, X., Sun, J., Liang, J., … & Fang, L. (2026). Coibamide analogue as a novel-class payload for antibody-drug conjugate. Journal of Medicinal Chemistry, 69(5), 5691-5702.